(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2020 Mar 11

PMID 32151049

Citations 3

Authors

Irina Velikyan

Affiliations

Soon will be listed here.

Abstract

The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine.

Citing Articles

Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.

Ismuha R, Ritawidya R, Daruwati I, Muchtaridi M Molecules. 2025; 29(24.

PMID: 39770150 PMC: 11679579. DOI: 10.3390/molecules29246062.

Unveiling the Potential of Prostate-Specific Membrane Antigen for Precision Diagnosis and Therapy of Prostate Cancer: A Radiopharmaceutical Perspective.

Hassan H, Othman M, Ashhar Z, Abdul Razak H, Ahmad Saad F Malays J Med Sci. 2024; 31(4):213-217.

PMID: 39247120 PMC: 11377010. DOI: 10.21315/mjms2024.31.4.17.

The emerging role and mechanism of HMGA2 in breast cancer.

Ma Q, Ye S, Liu H, Zhao Y, Zhang W J Cancer Res Clin Oncol. 2024; 150(5):259.

PMID: 38753081 PMC: 11098884. DOI: 10.1007/s00432-024-05785-4.

Predicting [Lu]Lu-HA-DOTATATE kidney and tumor accumulation based on [Ga]Ga-HA-DOTATATE diagnostic imaging using semi-physiological population pharmacokinetic modeling.

Siebinga H, de Wit-van der Veen B, Beijnen J, Stokkel M, Dorlo T, Huitema A EJNMMI Phys. 2023; 10(1):48.

PMID: 37615812 PMC: 10449733. DOI: 10.1186/s40658-023-00565-4.

References

Balogova S, Talbot J, Nataf V, Michaud L, Huchet V, Kerrou K . 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013; 40(6):943-66. PMC: 3644207. DOI: 10.1007/s00259-013-2342-x. View

Bouchelouche K, Choyke P . Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine. Curr Opin Oncol. 2016; 28(3):216-21. PMC: 5515231. DOI: 10.1097/CCO.0000000000000277. View

Blaickner M, Baum R . Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy. PET Clin. 2014; 9(1):99-112. DOI: 10.1016/j.cpet.2013.08.014. View

Haug A, Cindea-Drimus R, Auernhammer C, Reincke M, Beuschlein F, Wangler B . Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT. Radiology. 2013; 270(2):517-25. DOI: 10.1148/radiol.13122501. View

Sandstrom M, Lindskog K, Velikyan I, Wennborg A, Feldwisch J, Sandberg D . Biodistribution and Radiation Dosimetry of the Anti-HER2 Affibody Molecule 68Ga-ABY-025 in Breast Cancer Patients. J Nucl Med. 2016; 57(6):867-71. DOI: 10.2967/jnumed.115.169342. View

Toumpanakis C, Kim M, Rinke A, Bergestuen D, Thirlwell C, Khan M . Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology. 2014; 99(2):63-74. DOI: 10.1159/000358727. View

Beiderwellen K, Poeppel T, Hartung-Knemeyer V, Buchbender C, Kuehl H, Bockisch A . Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest Radiol. 2013; 48(5):273-9. DOI: 10.1097/RLI.0b013e3182871a7f. View

Kroiss A, Putzer D, Decristoforo C, Uprimny C, Warwitz B, Nilica B . 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT. Eur J Nucl Med Mol Imaging. 2013; 40(4):514-23. DOI: 10.1007/s00259-012-2309-3. View

Walker R, Smith G, Liu E, Moore B, Clanton J, Stabin M . Measured human dosimetry of 68Ga-DOTATATE. J Nucl Med. 2013; 54(6):855-60. PMC: 4472480. DOI: 10.2967/jnumed.112.114165. View

10.

Sorbye H, Kong G, Grozinsky-Glasberg S . PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Endocr Relat Cancer. 2019; 27(3):R67-R77. DOI: 10.1530/ERC-19-0400. View

11.

Menda Y, Ponto L, Schultz M, Zamba G, Watkins G, Bushnell D . Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors. Pancreas. 2013; 42(6):937-43. PMC: 3898770. DOI: 10.1097/MPA.0b013e318287ce21. View

12.

Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M . Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018; 36(25):2578-2584. PMC: 6366953. DOI: 10.1200/JCO.2018.78.5865. View

13.

Barber T, Singh A, Kulkarni H, Niepsch K, Billah B, Baum R . Clinical Outcomes of Lu-PSMA Radioligand Therapy in Earlier and Later Phases of Metastatic Castration-Resistant Prostate Cancer Grouped by Previous Taxane Chemotherapy. J Nucl Med. 2019; 60(7):955-962. DOI: 10.2967/jnumed.118.216820. View

14.

Ahlgren S, Orlova A, Wallberg H, Hansson M, Sandstrom M, Lewsley R . Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010; 51(7):1131-8. DOI: 10.2967/jnumed.109.073346. View

15.

Velikyan I . Continued rapid growth in (68) Ga applications: update 2013 to June 2014. J Labelled Comp Radiopharm. 2015; 58(3):99-121. DOI: 10.1002/jlcr.3250. View

16.

Lindstrom L, Karlsson E, Wilking U, Johansson U, Hartman J, Lidbrink E . Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30(21):2601-8. DOI: 10.1200/JCO.2011.37.2482. View

17.

Wulfert S, Kratochwil C, Choyke P, Afshar-Oromieh A, Mier W, Kauczor H . Multimodal imaging for early functional response assessment of (90)Y-/ (177)Lu-DOTATOC peptide receptor targeted radiotherapy with DW-MRI and (68)Ga-DOTATOC-PET/CT. Mol Imaging Biol. 2014; 16(4):586-94. PMC: 6336388. DOI: 10.1007/s11307-014-0722-7. View

18.

Hoffmann M, Wieler H, Baues C, Kuntz N, Richardsen I, Schreckenberger M . The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer. Urology. 2019; 130:1-12. DOI: 10.1016/j.urology.2019.04.004. View

19.

Kulkarni H, Prasad V, Kaemmerer D, Hommann M, Baum R . High uptake of (68)Ga-DOTATOC in spleen as compared to splenosis: measurement by PET/CT. Recent Results Cancer Res. 2012; 194:373-8. DOI: 10.1007/978-3-642-27994-2_19. View

20.

Wiesmuller M, Quick H, Navalpakkam B, Lell M, Uder M, Ritt P . Comparison of lesion detection and quantitation of tracer uptake between PET from a simultaneously acquiring whole-body PET/MR hybrid scanner and PET from PET/CT. Eur J Nucl Med Mol Imaging. 2012; 40(1):12-21. DOI: 10.1007/s00259-012-2249-y. View